Genitourinary Cancers

Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.

The combination of toripalimab and axitinib improved progression-free survival over single-agent sunitinib when used as first-line treatment in patients with intermediate to high risk, unresectable or distant metastatic renal cell carcinoma.

Treatment with nivolumab plus ipilimumab and a subsequent TKI was effective in patients with metastatic clear cell renal cell carcinoma.

The panel closes their discussion with a look at the standards for genetic counseling for patients with non-clear cell RCC.

The panel discusses the best approaches to treating patients with non-clear cell RCC.

Samer A. Srour, MB ChB, MS, explains the unique construction of ALLO-316, the potential for ALLO-316 to address an unmet need in patients with clear cell renal cell carcinoma, and how early data from the TRAVERSE study support the continued investigation of ALLO-316 in patients with CD70-expressing tumors.

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

The panel shares their preferred treatment regimens for patients with refractory renal cell carcinoma.

Hans Hammers, MD, presents a profile of a 47-year-old male with refractory renal cell carcinoma.

The allogeneic anti-CD70 CAR T-cell therapy ALLO-316 elicited signals of antitumor activity and showed a tolerable safety profile in patients with advanced or metastatic clear cell renal cell carcinoma.

Samer A. Srour, MB, ChB, MS, discusses the study design of the phase 1 TRAVERSE study, and key data on the use of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

The panel discusses recent clinical trial data in the adjuvant treatment of metastatic renal cell carcinoma.

Brian I. Rini, MD, FASCO, discusses the investigation of immunotherapy following disease progression on previous immunotherapy in patients with relapsed/refractory renal cell carcinoma.

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

The combination of durvalumab and guadecitabine generated early signs of clinical activity and tolerability in patients with advanced clear cell renal cell carcinoma, particularly those with no prior exposure to checkpoint inhibitors.

Christopher W. Ryan, MD, professor of medicine School of Medicine at the Oregon Health & Science University, discusses the evolution of therapeutic treatment approaches across the management treatment landscape of renal cell carcinoma.

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Laurence Albigès, MD, PhD, discusses on the safety and efficacy of cabozantinib in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component.

Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.

The panel provides an overview of novel double combination therapies currently under investigation.